An observational study in Glaucoma, sponsored by Centervue SpA. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Centervue SpA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.
Among the 53 studies in Glaucoma with a site in Italy, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2022, is one of 13 observational ones, and was the 40th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in Italy
Ages 18+
Fondazione G.B. Bietti, IRCCS · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+ · Healthy volunteers
Association for Innovation and Biomedical Research on Light and Image · Sites in Italy, Germany, Spain and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 14
First in 1993; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 64 across the 39 interventional studies, 200 across the 13 observational. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 53 have an industry lead sponsor. The 10 most frequent:
Centervue SpA is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Centervue SpA has 1 study filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07006194Università degli Studi 'G. d'Annunzio' Chieti e PescaraNicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) | 2026-12-31 |
| NCT07206628Laboratoires TheaReal-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Glaucoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.
Adult, both males and females, 40-90 years old with diagnosis of Glaucoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).
Equivalence will be defined as the 95% confidence Intervals of the mean difference between the slopes estimated with the two devices being within ± 0.1 dB/year
Time frame: 1 visit every 4 months (10 visits total), up to 3 years
Difference in time to identify progression between Compass and HFA using an event analysis
Time of first detectable change \[years\]
Time frame: 1 visit every 4 months (10 visits total), up to 3 years
Quantification of the effect of the integration of the rate of progression of structural metrics into the calculation of the rate of progression of the MD
Quantification of the effect of the integration of the rate of progression of structural metrics (mainly the retinal nerve fiber layer thickness, microns/year) into the calculation of the rate of progression of the MD. This effect will be quantified as the improvement in the equivalence metric defined for Outcome 1 The integration of structural OCT RNFL thickness information into progression analysis will be done using a Bayesian Linear Regression approach as suggested by Russel at al.\[\*\] \[\*\] R.A. Russel at al.; "Improved Estimates of Visual Field Progression Using Bayesian Linear Regression to Integrate Structural Information in Patients with Ocular Hypertension"; IOVS May 2012; 53(6): 2760-2769.
Time frame: 1 visit every 4 months (10 visits total), up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Nov 2028, 78 months after the start.
Of 135 observational studies under Glaucoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 208. This study's planned 78 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centervue SpA